AJP - Regu Add DOIs to your references at manuscript stage!
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Regul Integr Comp Physiol 288: R751-R758, 2005. First published November 18, 2004; doi:10.1152/ajpregu.00094.2004
0363-6119/05 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
288/3/R751    most recent
00094.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via ISI Web of Science (17)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kobelt, P.
Right arrow Articles by Mönnikes, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kobelt, P.
Right arrow Articles by Mönnikes, H.

APPETITE, OBESITY, DIGESTION, AND METABOLISM

CCK inhibits the orexigenic effect of peripheral ghrelin

Peter Kobelt,1 Johannes J. Tebbe,2 Ines Tjandra,1 Andreas Stengel,1 Hi-Gung Bae,3 Viola Andresen,4 Ivo R. van der Voort,4 Rüdiger W. Veh,5 Christoph R. Werner,1 Burghard F. Klapp,4 Bertram Wiedenmann,1 Lixin Wang,6 Yvette Taché,6 and Hubert Mönnikes1,4

1Department of Medicine, Division of Hepatology and Gastroenterology, Campus Virchow-Klinikum and 4Department of Medicine, Division of Psychosomatic Medicine and Psychotherapy, and 5Institute of Anatomy, Section of Electron Microscopy and Neuroanatomy, Campus Charité Mitte, Charité, Freie Universität and Humboldt-Universität Berlin, Berlin; 3Robert-Koch-Institute, Berlin; 2Department of Medicine, Division of Gastroenterology and Endocrinology, Philipps-Universität Marburg, Marburg, Germany; and 6Department of Medicine, CURE Digestive Diseases Research Center, Center for Neurosvisceral Sciences, Digestive Diseases Division UCLA, and Department of Veterans Affairs, Greater Los Angeles Healthcare System, Los Angeles, California

Submitted 11 February 2004 ; accepted in final form 26 October 2004


    ABSTRACT
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
CCK and ghrelin exert antagonistic effects on ingestive behavior. The aim of the present study was to investigate the interaction between ghrelin and CCK administered peripherally on food intake and neuronal activity in specific hypothalamic and brain stem nuclei, as assessed by c-Fos-like immunoreactivity (c-FLI) in nonfasted rats. Ghrelin (13 µg/kg body wt) injected intraperitoneally significantly increased the cumulative food intake when measured at 30 min and 1 h after injection, compared with the vehicle group (2.9 ± 1.0 g/kg body wt vs. 1.2 ± 0.5 g/kg body wt, P < 0.028). Sulfated CCK octapeptide (CCK-8S) (2 or 25 µg/kg body wt) injected simultaneously blocked the orexigenic effect of ghrelin (0.22 ± 0.13 g/kg body wt, P < 0.001 and 0.33 ± 0.23 g/kg body wt, P < 0.0008), while injected alone, both doses of CCK-8S exerted a nonsignificant trend to reduce food intake. Ghrelin (13 µg/kg body wt ip) markedly increased the number of c-FLI-positive neurons per section in the arcuate nucleus (ARC) compared with vehicle (median: 31.35 vs. 9.86, P < 0.0001). CCK-8S (2 or 25 µg/kg body wt ip) had no effect on neuronal activity in the ARC, as assessed by c-FLI (median: 5.33 and 11.21 cells per section), but blocked the ghrelin-induced increase of c-fos expression in this area when both peptides were administered simultaneously (median: 13.33 and 12.86 cells per section, respectively). Ghrelin at this dose had no effect on CCK-induced stimulation of c-fos expression in the paraventricular nucleus of the hypothalamus and the nucleus of the solitary tract. These results suggest that CCK abolishes ghrelin-induced food intake through dampening increased ARC neuronal activity.

brain-gut interaction; c-Fos; food intake; rat; brain


VARIOUS PEPTIDE HORMONES have been proposed to play an important role in the short-term regulation of food intake and satiety by influencing initiation and termination of meals (52). Compelling evidence for the existence of "satiety factors" came from initial observations in the 1970s demonstrating that peripheral CCK administered before food exposure causes a dose-dependent decrease in meal size (21). Since then, the satiating effect of CCK has been confirmed and extended by numerous reports (reviewed in Refs. 44 and 40). More recently, a 28-amino acid peptide hormone named ghrelin (27) has been identified as the first gut-brain peptide stimulating food intake in rats (33, 47, 55, 56), mice (4, 50), and humans (54).

CCK and ghrelin exert opposite actions on ingestive behavior. The potent orexigenic effect of peripheral injection of ghrelin (33, 47, 55, 56), the rise in plasma ghrelin levels induced by food deprivation or weight loss (15, 47) and the reduction of feeding in response to central administration of growth hormone secretagogue receptor (GHS-R) antagonist (3) in rodents implicate that endogenous ghrelin is involved in the initiation of food intake (14). On the other hand, several lines of evidence (reviewed in Ref. 40) have shown that endogenous CCK, released in the small intestine (36) in response to nutrients (28, 29), elicits potent anorexigenic effects and is involved in meal termination.

Recent reports indicate that both ghrelin and CCK effects on food intake are mediated at least partly by distinct brain nuclei, as demonstrated by changes in neuronal activity after peripheral administration of each peptide. Brain pathways activated by intraperitoneal injection of these peptides have been revealed by c-Fos-like immunoreactivity (c-FLI) (43). Sulfated CCK octapeptide (CCK-8S) induces c-FLI in the paraventricular nucleus of the hypothalamus (PVN) and selective medullary nuclei, namely, the nucleus of the solitary tract (NTS) and the area postrema (10, 17, 31, 34, 39). In contrast, ghrelin injected intraperitoneally induces c-fos expression, primarily in the arcuate nucleus of the hypothalamus (ARC) (24, 50), in the PVN (42), but not in the dorsal vagal complex (50) in rats and mice.

The satiation effect of CCK depends on signaling via the vagus nerve, as demonstrated by the significant attenuation of the feeding inhibitory properties of CCK by either surgical or chemical deafferentiation of the vagal nerve (41, 45). Likewise, a recent study indicates that vagal afferent-dependent mechanisms may be involved in peripheral ghrelin-induced increase in food intake and c-FLI in the ARC (16).

Collectively, these findings provide the conceptual framework for an antagonistic interaction between ghrelin and CCK to regulate food intake. Therefore, the initial purpose of the present study was to determine whether CCK modulates the orexigenic response to ghrelin. We investigated first the changes in food intake after simultaneous peripheral injection of ghrelin and increasing doses of CCK-8S in rats. Furthermore, recent electrophysiological studies (16), which demonstrated opposing effects of ghrelin and CCK on the afferent discharge activity of a vagal nerve filament, suggest that the dual influence of CCK and ghrelin may be associated with distinct neuronal activation patterns in the brain. Consequently, we also examined the influence of simultaneous intraperitoneal injection of ghrelin and CCK on the pattern of Fos expression in the PVN, ARC, and NTS. Brain nuclei were selected on the basis of the presence of GHS-R for ghrelin (ARC, PVN) and input from vagal afferent terminals after activation by peripheral CCK (NTS) (38, 51).


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Animals

Male Sprague-Dawley rats (Harlan-Winkelmann, Borchen, Germany) weighing 300–350 g were housed in groups of four rats per cage under conditions of controlled illumination (12:12-h light-dark cycle, lights on/off: 6:30 AM/6:30 PM), humidity, and temperature (22 ± 2°C). Animals were fed with a standard rat diet (Altromin, Lage, Germany) and tap water ad libitum. All animals were trained daily for 14 days before starting the experiments to accustom them to the behavioral studies. During this handling phase, holding them on their backs was practiced to prepare the animals for receiving an intraperitoneal injection. Similarly, every day, the animals were removed from their social group for 2 h and set in single cages. This period of social isolation exactly mimicked the time schedule of the experiments. Animals used for neuronal mapping (c-Fos) were handled daily for 5 days before the start of the experiment. They were also trained to be held in the back position for intraperitoneal injection and to be isolated in single cages for 2 h.

Animal care and experimental procedures followed institutional ethical guidelines and conformed to the requirements of the state authority for animal research conduct.

Peptide Preparation

Rat ghrelin [GSS(octanoyl)FLSPEHQKAQQRKESKKPPAKLQPR] (Bachem, Heidelberg, Germany) and CCK-8S [DT(SO3H) MGWMDF] (Bachem) were dissolved in distilled water (1 mg/ml) and stored at –20°C. Immediately before starting the experiments, peptides were diluted in vehicle solution consisting of sterile 0.15 M NaCl solution (Braun, Melsungen, Germany) to reach the final concentration of 13 µg/kg body wt (~4 nmol/kg body wt) for ghrelin and 2 or 25 µg/kg body wt for CCK-8S. Peptide solutions were kept on ice for the duration of the experiments.

Experiment 1: Effects of Peripheral Ghrelin and CCK-8S on Food Intake

All experiments were started at the same time of day (between 10:00 and 10:30), at 3.5 to 4 h after the start of the light cycle to achieve maximum consistency.

On the day of the experiment, freely fed animals were injected intraperitoneally simultaneously (final volume: 0.5 ml) with vehicle plus vehicle (0.15 M NaCl + 0.15 M NaCl, n = 15), ghrelin plus vehicle (13 µg/kg body wt + 0.15 M NaCl, n = 15), vehicle plus CCK-8S [0.15 M NaCl + 2 (n = 14) or 25 (n = 15) µg/kg body wt], or ghrelin plus CCK-8S [13 µg/kg body wt + 2 (n = 12) or 25 (n = 15) µg/kg body wt] and returned to single housing cages immediately after the injection. Thereafter, preweighed rat chow was made available to the animals. Food intake was determined by measuring the difference between the preweighed standard chow and the weight of chow at the end of the first 30 min, 1 h, and 2 h of food exposure. Selected doses of peptides were based on previous studies (31, 42, 57).

Experiment 2: Effects of Peripheral Ghrelin and CCK-8S on c-Fos-like-Immunoreactivity in the Hypothalamus and Brain Stem

Freely fed rats were injected intraperitoneally (final volume 0.5 ml) with vehicle plus vehicle (0.15 M NaCl + 0.15 M NaCl, n = 8), ghrelin plus vehicle (13 µg/kg body wt + 0.15 M NaCl, n = 8), vehicle plus CCK-8S [0.15 M NaCl + 2 (n = 4) or 25 (n = 4) µg/kg body wt], or ghrelin plus CCK-8S [13 µg/kg body wt +2 (n = 4) or 25 (n = 4) µg/kg body wt]. Immediately after injection, animals were deprived of food to avoid an influence of ghrelin-induced increase in food intake on c-Fos expression in the brain but had ad libitum access to water (50). At 90 min after the intraperitoneal injection, animals were deeply anesthetized with intraperitoneal injections of 100 mg/kg body wt ketamine (Ketanest, Curamed, Karlsruhe, Germany) and 10 mg/kg body wt xylazine (Rompun 2%, Bayer, Leverkusen, Germany) and heparinized with 2,500 U heparin intraperitoneally (Liquemin, Hoffmann-La Roche, Grenzach-Whylen, Germany). Transcardial perfusion was performed as described before (20) and consisted of a 10-s flush of a plasma substitute (Longasteril 70; Fresenius, Bad Homburg, Germany) followed by a mixture of 4% (wt/vol) paraformaldehyde, 0.05% (vol/vol) glutaraldehyde, and 0.2% (vol/vol) picric acid in 0.1 M phosphate buffer, pH 7.4, for 30 min and ended with a 5% (wt/vol) sucrose solution for 5 min. After dissection, brains were kept in a 5% (wt/vol) sucrose solution overnight and then cut into 1.0- to 4.5-mm coronal blocks, enclosing the hypothalamic and brain stem regions, respectively, using a Plexiglas brain matrix. For cryoprotection, blocks were moved through a sucrose gradient [15% (wt/vol) and 27.3% (wt/vol)], then shock-frozen in hexane at –70°C, and stored at –80°C until further processing.

Immunohistochemistry

Staining for c-Fos-like immunoreactivity. First, 25-µm, free-floating sections were pretreated with 1% (wt/vol) sodium borohydride in PBS for 15 min. Subsequently, sections were incubated in a solution containing 10% (wt/vol) BSA and 0.3% (vol/vol) Triton X-100 in PBS for 60 min for blockade of nonspecific antibody binding. Thereafter, the diluted primary antibody solution [rabbit anti-rat c-Fos protein; Oncogene Research Products, Boston, MA; 1:10,000 in a solution of 10% (wt/vol) BSA, 0.3% (vol/vol) Triton X-100, and 0.1% (wt/vol) sodium azide in PBS] was applied for 24 h at room temperature.

After rinsing sections in PBS three times and incubation in a solution containing 10% (wt/vol) BSA and 0.3% vol/vol Triton X-100 for 60 min, FITC-labeled goat anti-rabbit IgG (Sigma, St. Louis, MO) was applied for 12 h at room temperature in an appropriate dilution [1:800 in 10% (wt/vol) BSA in PBS]. Sections were rinsed in PBS three times again and stained with propidium iodide (2.5 µg/ml in PBS) for 15 min to counterstain cell chromatin. Tissue sections were finally embedded in 15 µl antifading solution, 100 mg/ml 1,4-diazabicyclo[2.2.2]octane (Sigma, St. Louis, MO), in 90% vol/vol glycerin, 10% vol/vol PBS, pH 7.4], and analyzed using a confocal laser scanning microscope (cLSM 510, Zeiss).

Data and Statistical Analysis

Immunohistochemistry. Semiquantitative assessment of c-Fos-like immunoreactivity (c-FLI) was achieved by counting the number of c-FLI-positive cells. Cells with green nuclear staining were considered c-FLI positive. Every second of all consecutive coronal 25-µm sections was counted for c-FLI-positive staining bilaterally in the ARC, PVN, and NTS throughout their rostrocaudal extent. Anatomic correlations were made according to landmarks given in a stereotaxic atlas (35). c-FLI-positive cells were counted in 10 sections of the PVN per rat and 15 sections of the ARC and NTS per rat. The investigator counting the number of c-Fos-positive cells was blinded to treatments received by the animals.

The average number of c-FLI-positive cells per section for the brain nuclei mentioned above was calculated for each rat. Data are expressed as median and interquartile ranges of the average number of cells per section. Differences between groups were evaluated by the nonparametric Kruskal-Wallis and Mann-Whitney U-tests; P < 0.05 was considered significant.

Feeding experiments. The cumulative food intake monitored at the end of the first 30-min, 1-h, and 2-h periods after peptide or vehicle injection was expressed as food intake (g) per body weight (kg). Data are expressed as means ± SE and analyzed by ANOVA. Differences between groups were evaluated by the least significant difference test; P < 0.05 was considered significant.


    RESULTS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Experiment 1: Effects of Ghrelin and CCK-8S Injected Intraperitoneally on Food Intake

Ghrelin (13 µg /kg body wt ip) significantly increased the food intake within the first half hour after intraperitoneal injection of vehicle plus peptide (2.89 ± 1.04 g/kg body wt) compared with the intraperitoneal vehicle plus vehicle group (1.23 ± 0.52 g/kg body wt, P < 0.028; Fig. 1). CCK-8S injected intraperitoneally at either 2 or 25 µg/kg body wt, respectively, simultaneously with ghrelin (13 µg/kg body wt) blocked the stimulatory effect of ghrelin on food intake (0.22 ± 0.13 and 0.33 ± 0.23 g/kg body wt, respectively; P < 0.001; Fig. 1). CCK-8S injected intraperitoneally alone at 2 or 25 µg/kg body wt tends to decrease food intake during the first 30 min (0.68 ± 0.4 g/kg body wt; P > 0.46; 0.05 ± 0.05 g/kg body wt, P > 0.11, respectively) compared with the vehicle plus vehicle group, although it did not reach statistical significance (Fig. 1).



View larger version (29K):
[in this window]
[in a new window]
 
Fig. 1. Effects of ghrelin, CCK, and ghrelin + CCK injected intraperitoneally on 2-h food intake. Freely fed rats were injected intraperitoneally with vehicle, sulfated cholecystokinin octapeptide (CCK-8S) (2 or 25 µg/kg body wt), ghrelin (13 µg/kg body wt) + CCK-8S (2 or 25 µg/kg body wt), or ghrelin (13 µg/kg body wt) and food intake (expressed as g/kg body wt) was measured at 0.5, 1, and 2 h. Ghrelin induced a significant increase in food intake during the first hour compared with vehicle. The effect of ghrelin was abolished by simultaneous treatment with CCK-8S at doses of 2 or 25 µg/kg body wt. A nonsignificant inhibitory effect of CCK on food intake was observed under these experimental conditions. Data are expressed as means ± SE. *P < 0.05 vs. vehicle, vs. 2 or 25 µg CCK-8S/kg body wt and vs. ghrelin + 2 or 25 µg CCK-8S/kg body wt; #P < 0.05 vs. ghrelin + 2 µg CCK-8S/kg body wt; &P < 0.05 vs. ghrelin + 2 µg CCK-8S/kg body wt.

 
At 1 h after ghrelin injection, the significant increase in the cumulative food intake compared with the vehicle plus vehicle group was still observed (3.83 ± 1.15 vs. 1.84 ± 0.73 g/kg body wt, P < 0.044; Fig. 1). CCK-8S at 2 or 25 µg/kg body wt injected intraperitoneally simultaneously with ghrelin (13 µg/kg body wt) inhibited the stimulatory effect of ghrelin on food intake (0.22 ± 0.13 g/kg body wt, P < 0.008 and 0.65 ± 0.42 g/kg body wt, P < 0.0016, respectively; Fig. 1). In comparison to the vehicle plus vehicle group, CCK injected intraperitoneally alone at both doses of 2 or 25 µg/kg body wt did not significantly modify food intake (1.96 ± 0.82 g/kg body wt, P > 0.87; 0.31 ± 0.26 g/kg body wt, P > 0.48, respectively; Fig. 1).

At 2 h after administration of ghrelin, cumulative food intake values were similar between the ghrelin plus vehicle group and the vehicle plus vehicle group (ghrelin 5.2 ± 1.5 g/kg body wt vs. vehicle 4.1 ± 1.2 g/kg body wt, P > 0.49; Fig. 1). Interestingly, despite the lack of a significant influence of CCK alone at both doses on food intake, we observed a decrease in food intake in comparison with the vehicle group when 2 µg CCK-8S/kg body wt was administered together with ghrelin (4.1 ± 1.2 g/kg body wt vs. 0.83 ± 0.72 g/kg body wt, P < 0.048; Fig. 1). Further, a significant difference in reduction of food intake was observed between the vehicle plus 2 µg CCK-8S/kg body wt group and the ghrelin plus 2 µg CCK-8S/kg body wt group (4.36 ± 1.39 g/kg body wt vs. 0.83 ± 0.72 g/kg body wt, P < 0.036; Fig. 1).

Experiment 2: Effects of Ghrelin and CCK-8S Injected Intraperitoneally on c-fos Expression in Hypothalamic and Medullary Nuclei

Ghrelin (13 µg/kg body wt ip) induced a robust increase in the density of c-FLI-positive neurons in the ARC, predominantly in the ventromedial part (Fig. 2), compared with vehicle (median number of c-FLI-positive neurons per section: 31.35 vs. 9.86, P < 0.0001; Fig. 3). The effect of peripheral ghrelin (13 µg ghrelin/kg body wt) on neuronal activity in the ARC was significantly diminished by simultaneous treatment with CCK-8S injected intraperitoneally at a dose of 2 µg/kg body wt (13.33 neurons per section, P < 0.008 vs. ghrelin dose; Fig. 3) or 25 µg/kg body wt (12.86 neurons per section, P < 0.004 vs. ghrelin dose; Fig. 3), as shown by the few c-FLI-positive nuclei found in the ARC (Fig. 2). CCK-8S alone had no effect on neuronal activity in the ARC, as assessed by c-FLI, when the peptide was injected at doses of 2 or 25 µg/kg body wt (5.33 and 11.21 cells per section, respectively; Fig. 3).



View larger version (63K):
[in this window]
[in a new window]
 
Fig. 2. Effects of ghrelin, CCK, and ghrelin + CCK injected intraperitoneally on c-Fos-like immunoreactivity (c-FLI) in the arcuate nucleus (ARC) of the hypothalamus. At treatment with 13 µg ghrelin/kg body wt (A), we observed c-FLI (green staining) at 90 min after intraperitoneal injection of the peptides in freely fed rats (n = 8/group). At intraperitoneal injection of ghrelin (13 µg/kg body wt) + 2 (G) or 25 (H) µg CCK-8S/kg body wt (n = 4/group), 2 µg CCK-8S/kg body wt (n = 4/group) (B) and 25 µg CCK-8S/kg body wt (n = 4/group) (C) alone, or saline injection (n = 8/group) (I), none or only a few c-FLI-positive neurons were found in the ARC. Cell nuclei are stained red as a result of the counterstaining with propidium iodide in the same slice from animals treated with ghrelin (D), ghrelin + 2 (J) or 25 (K) µg CCK-8S/kg body wt, 2 (E) or 25 (F) µg CCK-8S/kg body wt alone, and saline (L). The white line delineates the area of the hypothalamic ARC in accordance with landmarks from the Paxinos and Watson rat brain atlas (35). White scale bar represents 100 µm. 3V, third ventricle; ME, median eminence.

 


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 3. Effects of ghrelin, CCK, and ghrelin + CCK injected intraperitoneally on the number of c-FLI-positive neurons in the ARC of the hypothalamus. Freely fed rats were injected intraperitoneally with vehicle (NaCl), CCK-8S (2 or 25 µg/kg body wt), ghrelin (13 µg/kg body wt), or ghrelin + CCK-8S (13 µg/kg body wt + 2 or 25 µg/kg body wt), and were euthanized 90 min later to process brains for c-FLI. Data are presented by box and whiskers plots. The upper hinge of the box represents the 75th and the lower one the 25th percentile, respectively. The median is shown as a line across the box. The whiskers above and below the boxes represent the largest and smallest observed scores that are <1.5 box lengths from the end of the box. *P < 0.05 vs. vehicle, 2 or 25 µg CCK-8S/kg body wt, and ghrelin + 2 or 25 µg CCK-8S/kg body wt.

 
The density of c-FLI-positive neurons in the PVN and NTS (data shown in Figs. 4 and 5) was dose dependently increased after treatment with CCK-8S (2 or 25 µg/kg body wt ip). Simultaneous treatment with ghrelin (13 µg/kg body wt + 2 or 25 µg CCK-8S/kg body wt ip) did not affect the CCK-induced increase in c-fos expression in the PVN and NTS (Figs. 4 and 5).



View larger version (23K):
[in this window]
[in a new window]
 
Fig. 4. Effects of ghrelin, CCK, and ghrelin + CCK injected intraperitoneally on the number of c-FLI-positive neurons in the paraventricular nucleus of the hypothalamus (PVN) Freely fed rats were injected intraperitoneally with vehicle (NaCl), CCK-8S (2 or 25 µg/kg body wt), ghrelin (13 µg/kg body wt), or ghrelin + CCK-8S (13 µg/kg body wt + 2 or 25 µg/kg body wt) and were euthanized 90 min later to process brains for c-FLI. Data are presented by box and whiskers plots, as in Fig. 3. *P < 0.05 vs. vehicle; #P < 0.05 vs. ghrelin.

 


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 5. Effects of ghrelin, CCK, and ghrelin + CCK injected intraperitoneally on the number of c-FLI-positive neurons in the nucleus of the solitary tract (NTS). Freely fed rats were injected intraperitoneally with vehicle (NaCl), CCK-8S (2 or 25 µg/kg body wt), ghrelin (13 µg/kg body wt), or ghrelin + CCK-8S (13 µg/kg body wt + 2 or 25 µg/kg body wt) and were euthanized 90 min later to process brains for c-FLI. Data are presented by box and whiskers plots, as in Fig. 3. *P < 0.05 vs. vehicle; #P < 0.05 vs. ghrelin.

 
In the present study, we could also show that ghrelin administered intraperitoneally caused a significant increase in the number of c-FLI-positive neurons in the PVN compared with the vehicle group (median number of c-FLI-positive cells per section: 50.56 vs. 20.25, P < 0.02; Fig. 4).


    DISCUSSION
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Short-term control of ingestive behavior is regulated by various gut-derived peptides such as CCK and ghrelin (21). In the present study, we provide evidence for an inhibition of the stimulatory effect of peripheral ghrelin on food intake and neuronal activation in the hypothalamic ARC nucleus by peripheral CCK-8S in rats.

Ghrelin injected intraperitoneally exerted an orexigenic effect in freely fed rats, which is in agreement with earlier studies (33, 47, 55, 56). The time course study indicates that CCK-8S at doses of 2 or 25 µg/kg body wt induced a suppression of ghrelin stimulatory action on food intake that was similarly rapid in onset (within 30 min) and duration (over 2 h). Interestingly, the reduction in food intake in animals treated with ghrelin plus CCK-8S at both doses was more pronounced and longer lasting than with treatment with CCK-8S alone. It may be speculated that this effect of a combined application of both peptides is mediated via hypothalamic mechanisms, since peripheral injection of ghrelin and CCK-8S affects neuronal activity in different hypothalamic nuclei, as shown by changes in c-fos expression. However, the mechanisms and pathways still have to be elucidated in detail. CCK still displays a similar potency to reduce the 1-h accumulated food intake increase when injected intraperitoneally at 2 or 25 µg/kg body wt, resulting in 94% and 83% reduction, respectively. Thus both doses of CCK in our experiments act to suppress ghrelin-induced food intake in rats. It has been shown that doses of 8 µg CCK-8S/kg body wt ip or higher might induce unspecific effects in laboratory animals (e.g., nausea, taste aversion) (32). However, doses less than 8 µg CCK-8S/kg body wt do not induce unspecific effects on behavior in rats (32), suggesting that the observed effect of CCK on ghrelin-induced increase in food intake is specific to the peptide.

Various medullary and hypothalamic brain nuclei have been suggested to convey nutrient-related signals from the gastrointestinal tract to higher brain centers (18, 19, 52). In particular, several studies established that both CCK and ghrelin are gut peptides that regulate ingestive behavior by modulating the activity of distinct brain nuclei (22, 24, 49, 50, 57), as shown by a specific pattern of c-FLI in the brain (10, 17, 24, 31, 34, 39, 50). It therefore seemed reasonable to assume that the interaction between the two peptides to regulate food intake may be accompanied by changes in the specific patterns of neuronal activation in the hypothalamus and/or the brain stem. The intraperitoneal injection of ghrelin did not influence intraperitoneal CCK-induced Fos expression in the PVN and NTS. By contrast, CCK-8S at both doses of 2 and 25 µg/kg body wt significantly reduced the intraperitoneal ghrelin-induced increase of c-Fos density in the ARC monitored at 90 min postinjection by 57% and 59%, respectively.

The effect of ghrelin on ARC neurons has been recently characterized. First, peripheral administration of ghrelin induces a significant increase of c-Fos-positive neurons in the ARC in rats and mice (24). Furthermore, it has been found that a large population of c-Fos-positive neurons contains the orexigenic peptide neuropeptide Y (NPY) (50). Thus one could speculate that such brain areas are involved in the mechanisms that regulate meal initiation. Consequently, the inhibition of NPY/agouti-related protein neurons in the ARC by CCK could be involved in the suppressive effects of CCK on ghrelin-induced stimulation of food intake. The pathways by which intraperitoneal ghrelin signals to the ARC are impaired by intraperitoneal CCK could not conclusively be identified from the present study.

In our experiments, both doses of CCK-8S (2 and 25 µg/kg body wt) caused a significant reduction of the ghrelin-induced increase of c-Fos density in the ARC and blocked the ghrelin-induced stimulation of food intake. The control of meal size by CCK has been reported to involve brain stem mechanisms (23). However, it has also been shown that bilateral midbrain transection rostral to the NTS blocks peripheral injection of CCK-induced reduction of feeding (12). Furthermore, the destruction of the PVN (11) or the dorsomedial nucleus of the hypothalamus (6, 7) inhibits the suppression of feeding induced by peripheral CCK. Consistent with these functional studies, CCK induced a significant increase in c-fos expression in the NTS and PVN at 90 min after intraperitoneal injection, as previously reported (10, 17, 31, 34, 39). The PVN and NTS might exert an inhibitory influence on the neuronal activity in the ARC because both nuclei send direct projections to the ARC (26, 37). Therefore, it seems possible that the inhibition of ghrelin-induced activation of ARC neurons by CCK is mediated by afferent projections from the PVN and/or NTS.

Other recent studies support a role of the vagus in ghrelin signaling pathways to the ARC. Date and colleagues (16) have shown that both subdiaphragmatic or gastric vagotomy and perivagal capsaicin treatment attenuate the increase in the density of c-Fos in the ARC after intravenous injection of ghrelin. Also, in such vagally impaired animals, the change in food intake after ghrelin administration decreased significantly. Moreover, afferent fibers of the vagal nerve carry the GHS-R (16). Ghrelin is an endogenous ligand of the GHS-R (27). It is also well known that vagal afferent fibers play a primary role in the satiety effect of a low dose of CCK (41, 45). Therefore, one could speculate that the inhibition of the ghrelin effect by CCK is mediated by mechanisms involving afferent fibers of the vagal nerve. Recent electrophysiological studies showed opposing effects of ghrelin and CCK on the multiunit afferent discharge activity of gastric vagal nerve filaments (16). However, more recent electrophysiological studies looking at single gastric vagal afferent units in response to ghrelin and CCK injected intravenously showed that ghrelin has both inhibitory and excitatory action on vagal afferent activity, while application of CCK results in a constant stimulatory effect (1). In the present study the NTS, which receives vagal afferent input (38), was activated similarly by CCK injected alone or with ghrelin, suggesting that additional mechanisms unrelated to vagal afferent signaling pathways may also play a role. Recently, in vitro CCK studies of mouse brain slices demonstrated that a subset of neurons in the ARC responds to CCK by slowing the firing of ARC type-C neurons (9). Thus it cannot be ruled out that peripheral CCK reaching neurons in the ARC through the "leaky" blood-brain barrier at the median eminence could affect the responsiveness of ARC neurons to peripheral ghrelin (9). Further electrophysiological studies will be needed to support the hypothesis of a direct central effect of peripheral CCK on ARC neurons sensitive to peripheral ghrelin. Therefore, the present observations that peripheral CCK inhibits peripheral ghrelin-induced activation of ARC neurons, as assessed by c-FLI, and abolishes ghrelin-induced food intake in rats could be also explained by such a local hypothalamic mechanism.

In studies related to c-fos expression in the brain induced by peripheral injection of CCK, and ghrelin injected alone or in combination, fed animals were subsequently deprived of solid food to avoid confounding effects of food intake. Acute stress (swimming stress) in rats showed increased c-fos expression distinctly in the lateral part of the ARC (13). However, it is unlikely that the food deprivation may induce stress in ghrelin-treated rats and possibly change the c-fos expression in the ARC. We observed c-Fos signals in the medial part of the ARC after intraperitoneal injection of ghrelin, as previously reported (24, 50), and only a few signals of c-Fos in the lateral part of the ARC.

It has been well established that CCK suppresses food intake after intraperitoneal injection in rats (2, 8), although only certain experimental conditions reveal the anorexigenic effect of CCK (44, 48). The present studies were performed in nonfasted rats to detect meal initiation and its blockade. During the first half hour after CCK injection, we observed a trend toward a reduction in food intake, although this effect did not reach statistical significance. Most studies showing an inhibitory effect of peripheral CCK on food intake were conducted in fasted animals to assess the termination of hyperphagia induced by a fast in rats or mice (5, 30). Thus the nonfasting state of the animals is very likely the reason for the lack of a significant reduction of food intake at treatment with both doses of CCK in the present study.

Evidence supports that peripheral ghrelin interferes not only with the CCK-related mechanism in the regulation of satiety and food intake but also with other neuropeptides involved in homeostatic regulation of energy intake and expenditure. Hewson et al. (25) have shown an increase of c-Fos-positive neurons in the ARC, induced by intravenous administration of growth hormone-releasing peptide (GHRP-6), a synthetic growth hormone secretagogue (25). This effect of GHRP-6 on ARC neurons was diminished by central administration of leptin (25). Further, it has been shown that neurons in the ARC that are c-Fos positive, as a result of peripheral administration of ghrelin, carry the leptin receptor (Ob-R) (46) and that there is an interaction between ghrelin and leptin in the regulation of food intake (33).

In summary, the present data show that the orexigenic effect of peripheral ghrelin is modulated by peripheral CCK in freely fed rats. The stimulation of food intake and neuronal activity in the ARC induced by ghrelin administered intraperitoneally is abolished by intraperitoneal CCK. In contrast, the activation of neurons in the PVN and NTS induced by peripheral CCK is not influenced by ghrelin. These observations suggest that ARC neurons play a role in the mediation of ghrelin-induced stimulation of food intake and also in the mechanisms involved in the inhibition of the ghrelin-induced increase in food intake by peripheral CCK. However, it still has to be determined whether the influence of peripheral CCK on ghrelin-induced changes in food intake and neuronal activity in the hypothalamus occurs primarily at the level of peripheral afferents, like the vagus nerve, or at the central level.


    GRANTS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
This work was supported by a grant from the German Research Foundation (DFG) to H. Mönnikes (DFG: Mö 458/4–1) and grants to H. Mönnikes (Charité: UFF 2002–503) and Y. Taché (Research Career Scientist Award, Department of Veterans Affairs and National Institute of Diabetes and Digestive and Kidney Diseases Grant DK-30110).


    ACKNOWLEDGMENTS
 
We are grateful to P. Moschansky and J. Prasolov for their excellent technical support.


    FOOTNOTES
 

Address for reprint requests and other correspondence: H. Mönnikes, Dept. of Medicine, Div. of Hepatology and Gastroenterology, Charité, Medical Faculty of Freie Universität and Humboldt-Universität at Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany (E-mail: hubert.moennikes{at}charite.de)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


    REFERENCES
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Adelson DW, Kosoyan H, Chun E, Million M, and Taché Y. Vago-vagal reflex responses to iv ghrelin and CCK in rats: a combined ultrasonometry-dual nerve recording study (Abstract). Gastroenterology 126: A-588, 2004.
  2. Antin J, Gibbs J, Holt J, Young RC, and Smith GP. Cholecystokinin elicits the complete behavioral sequence of satiety in rats. J Comp Physiol Psychol 89: 784–790, 1975.[CrossRef][ISI][Medline]
  3. Asakawa A, Inui A, Kaga T, Katsuura G, Fujimiya M, Fujino MA, and Kasuga M. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 52: 947–952, 2003.[Abstract/Free Full Text]
  4. Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Ueno N, Makino S, Fujimiya M, Niijima A, Fujino MA, and Kasuga M. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 120: 337–345, 2001.[CrossRef][ISI][Medline]
  5. Barrachina MD, Martinez V, Wang L, Wei JY, and Taché Y. Synergistic interaction between leptin and cholecystokinin to reduce short-term food intake in lean mice. Proc Natl Acad Sci USA 94: 10455–10460, 1997.[Abstract/Free Full Text]
  6. Bellinger LL and Bernardis LL. Suppression of feeding by cholecystokinin but not bombesin is attenuated in dorsomedial hypothalamic nuclei lesioned rats. Peptides 5: 547–552, 1984.[CrossRef][ISI][Medline]
  7. Bellinger LL, Bernardis LL, and Williams FE. Naloxone suppression of food and water intake and cholecystokinin reduction of feeding is attenuated in weanling rats with dorsomedial hypothalamic lesions. Physiol Behav 31: 839–846, 1983.[CrossRef][Medline]
  8. Billington CJ, Levine AS, and Morley JE. Are peptides truly satiety agents? A method of testing for neurohumoral satiety effects. Am J Physiol Regul Integr Comp Physiol 245: R920–R926, 1983.[Abstract/Free Full Text]
  9. Burdakov D and Ashcroft FM. Cholecystokinin tunes firing of an electrically distinct subset of arcuate nucleus neurons by activating A-type potassium channels. J Neurosci 22: 6380–6387, 2002.[Abstract/Free Full Text]
  10. Chen DY, Deutsch JA, Gonzalez MF, and Gu Y. The induction and suppression of c-fos expression in the rat brain by cholecystokinin and its antagonist L364,718. Neurosci Lett 149: 91–94, 1993.[CrossRef][ISI][Medline]
  11. Crawley JN and Kiss JZ. Paraventricular nucleus lesions abolish the inhibition of feeding induced by systemic cholecystokinin. Peptides 6: 927–935, 1985.[CrossRef][ISI][Medline]
  12. Crawley JN, Kiss JZ, and Mezey E. Bilateral midbrain transections block the behavioral effects of cholecystokinin on feeding and exploration in rats. Brain Res 322: 316–321, 1984.[CrossRef][ISI][Medline]
  13. Cullinan WE, Herman JP, Battaglia DF, Akil H, and Watson SJ. Pattern and time course of immediate early gene expression in rat brain following acute stress. Neuroscience 64: 477–505, 1995.[CrossRef][ISI][Medline]
  14. Cummings DE and Foster KE. Ghrelin-leptin tango in body-weight regulation. Gastroenterology 124: 1532–1535, 2003.[CrossRef][ISI][Medline]
  15. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, and Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50: 1714–1719, 2001.[Abstract/Free Full Text]
  16. Date Y, Murakami N, Toshinai K, Matsukura S, Niijima A, Matsuo H, Kangawa K, and Nakazato M. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 123: 1120–1128, 2002.[CrossRef][ISI][Medline]
  17. Day HE, McKnight AT, Poat JA, and Hughes J. Evidence that cholecystokinin induces immediate early gene expression in the brainstem, hypothalamus and amygdala of the rat by a CCKA receptor mechanism. Neuropharmacology 33: 719–727, 1994.[CrossRef][ISI][Medline]
  18. Elmquist JK, Elias CF, and Saper CB. From lesions to leptin: hypothalamic control of food intake and body weight. Neuron 22: 221–232, 1999.[CrossRef][ISI][Medline]
  19. Flier JS,. and Maratos-Flier E Obesity and the hypothalamus: novel peptides for new pathways. Cell 92: 437–440, 1998.[CrossRef][ISI][Medline]
  20. Geisler S, Heilmann H, and Veh RW. An optimized method for simultaneous demonstration of neurons and myelinated fiber tracts for delineation of individual trunco- and palliothalamic nuclei in the mammalian brain. Histochem Cell Biol 117: 69–79, 2002.[CrossRef][ISI][Medline]
  21. Gibbs J, Young RC, and Smith GP. Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol 84: 488–495, 1973.[CrossRef][ISI][Medline]
  22. Glatzle J, Kreis ME, Kawano K, Raybould HE, and Zittel TT. Postprandial neuronal activation in the nucleus of the solitary tract is partly mediated by CCK-A receptors. Am J Physiol Regul Integr Comp Physiol 281: R222–R229, 2001.[Abstract/Free Full Text]
  23. Grill HJ and Smith GP. Cholecystokinin decreases sucrose intake in chronic decerebrate rats. Am J Physiol Regul Integr Comp Physiol 254: R853–R856, 1988.[Abstract/Free Full Text]
  24. Hewson AK and Dickson SL. Systemic administration of ghrelin induces Fos and Egr-1 proteins in the hypothalamic arcuate nucleus of fasted and fed rats. J Neuroendocrinol 12: 1047–1049, 2000.[CrossRef][ISI][Medline]
  25. Hewson AK, Tung LY, Connell DW, Tookman L, and Dickson SL. The rat arcuate nucleus integrates peripheral signals provided by leptin, insulin, and a ghrelin mimetic. Diabetes 51: 3412–3419, 2002.[Abstract/Free Full Text]
  26. Ito H and Seki M. Ascending projections from the area postrema and the nucleus of the solitary tract of Suncus murinus: anterograde tracing study using Phaseolus vulgaris leucoagglutinin. Okajimas Folia Anat Jpn 75: 9–31, 1998.[Medline]
  27. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, and Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402: 656–660, 1999.[CrossRef][Medline]
  28. Li Y and Owyang C. Peptone stimulates CCK-releasing peptide secretion by activating intestinal submucosal cholinergic neurons. J Clin Invest 97: 1463–1470, 1996.[ISI][Medline]
  29. Liddle RA, Green GM, Conrad CK, and Williams JA. Proteins but not amino acids, carbohydrates, or fats stimulate cholecystokinin secretion in the rat. Am J Physiol Gastrointest Liver Physiol 251: G243–G248, 1986.[Abstract/Free Full Text]
  30. McMinn JE, Sindelar DK, Havel PJ, and Schwartz MW. Leptin deficiency induced by fasting impairs the satiety response to cholecystokinin. Endocrinology 141: 4442–4448, 2000.[Abstract/Free Full Text]
  31. Mönnikes H, Lauer G, and Arnold R. Peripheral administration of cholecystokinin activates c-fos expression in the locus coeruleus/subcoeruleus nucleus, dorsal vagal complex and paraventricular nucleus via capsaicin-sensitive vagal afferents and CCK-A receptors in the rat. Brain Res 770: 277–288, 1997.[CrossRef][ISI][Medline]
  32. Morley JE. Neuropeptide regulation of appetite and weight. Endocr Rev 8: 256–287, 1987.[CrossRef][ISI][Medline]
  33. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, and Matsukura S. A role for ghrelin in the central regulation of feeding. Nature 409: 194–198, 2001.[CrossRef][Medline]
  34. Olson BR, Hoffman GE, Sved AF, Stricker EM, and Verbalis JG. Cholecystokinin induces c-fos expression in hypothalamic oxytocinergic neurons projecting to the dorsal vagal complex. Brain Res 569: 238–248, 1992.[CrossRef][ISI][Medline]
  35. Paxinos G and Watson C. The Rat Brain in Stereotaxic Coordinates. San Diego: Academic, 1997.
  36. Polak JM, Bloom SR, Rayford PL, Pearse AG, Buchan AM, and Thompson JC. Identification of cholecystokinin-secreting cells. Lancet 2: 1016–1018, 1975.[ISI][Medline]
  37. Ranson RN, Motawei K, Pyner S, and Coote JH. The paraventricular nucleus of the hypothalamus sends efferents to the spinal cord of the rat that closely appose sympathetic preganglionic neurones projecting to the stellate ganglion. Exp Brain Res 120: 164–172, 1998.[CrossRef][ISI][Medline]
  38. Raybould HE, Gayton RJ, and Dockray GJ. Mechanisms of action of peripherally administered cholecystokinin octapeptide on brain stem neurons in the rat. J Neurosci 8: 3018–3024, 1988.[Abstract]
  39. Rinaman L, Hoffman GE, Dohanics J, Le WW, Stricker EM, and Verbalis JG. Cholecystokinin activates catecholaminergic neurons in the caudal medulla that innervate the paraventricular nucleus of the hypothalamus in rats. J Comp Neurol 360: 246–256, 1995.[CrossRef][ISI][Medline]
  40. Ritter RC, Covasa M, and Matson CA. Cholecystokinin: proofs and prospects for involvement in control of food intake and body weight. Neuropeptides 33: 387–399, 1999.[CrossRef][ISI][Medline]
  41. Ritter RC and Ladenheim EE. Capsaicin pretreatment attenuates suppression of food intake by cholecystokinin. Am J Physiol Regul Integr Comp Physiol 248: R501–R504, 1985.[Abstract/Free Full Text]
  42. Rüter J, Kobelt P, Tebbe JJ, Avsar Y, Veh R, Wang L, Klapp BF, Wiedenmann B, Taché Y, and Mönnikes H. Intraperitoneal injection of ghrelin induces Fos expression in the paraventricular nucleus of the hypothalamus in rats. Brain Res 991: 26–33, 2003.[CrossRef][ISI][Medline]
  43. Sagar SM, Sharp FR, and Curran T. Expression of c-fos protein in brain: metabolic mapping at the cellular level. Science 240: 1328–1331, 1988.[Abstract/Free Full Text]
  44. Silver AJ and Morley JE. Role of CCK in regulation of food intake. Prog Neurobiol 36: 23–34, 1991.[CrossRef][ISI][Medline]
  45. Smith GP, Jerome C, Cushin BJ, Eterno R, and Simansky KJ. Abdominal vagotomy blocks the satiety effect of cholecystokinin in the rat. Science 213: 1036–1037, 1981.[Abstract/Free Full Text]
  46. Traebert M, Riediger T, Whitebread S, Scharrer E, and Schmid HA. Ghrelin acts on leptin-responsive neurones in the rat arcuate nucleus. J Neuroendocrinol 14: 580–586, 2002.[CrossRef][ISI][Medline]
  47. Tschöp M, Smiley DL, and Heiman ML. Ghrelin induces adiposity in rodents. Nature 407: 908–913, 2000.[CrossRef][Medline]
  48. Voigt JP, Huston JP, Voits M, and Fink H. Effects of cholecystokinin octapeptide (CCK-8) on food intake in adult and aged rats under different feeding conditions. Peptides 17: 1313–1315, 1996.[CrossRef][ISI][Medline]
  49. Wang L, Martinez V, Barrachina MD, and Taché Y. Fos expression in the brain induced by peripheral injection of CCK or leptin plus CCK in fasted lean mice. Brain Res 791: 157–166, 1998.[CrossRef][ISI][Medline]
  50. Wang L, Saint-Pierre DH, and Taché Y. Peripheral ghrelin selectively increases Fos expression in neuropeptide Y—synthesizing neurons in mouse hypothalamic arcuate nucleus. Neurosci Lett 325: 47–51, 2002.[CrossRef][ISI][Medline]
  51. Willesen MG, Kristensen P, and Romer J. Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat. Neuroendocrinology 70: 306–316, 1999.[CrossRef][ISI][Medline]
  52. Woods SC, Seeley RJ, Porte D Jr. and Schwartz MW Signals that regulate food intake and energy homeostasis. Science 280: 1378–1383, 1998.[Abstract/Free Full Text]
  53. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei MA, and Bloom SR. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86: 5992, 2001.[Abstract/Free Full Text]
  54. Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA, Batterham RL, Taheri S, Stanley SA, Ghatei MA, and Bloom SR. Ghrelin causes hyperphagia and obesity in rats. Diabetes 50: 2540–2547, 2001.[Abstract/Free Full Text]
  55. Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, Kennedy AR, Roberts GH, Morgan DG, Ghatei MA, and Bloom SR. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 141: 4325–4328, 2000.[Abstract/Free Full Text]
  56. Zittel TT, Glatzle J, Kreis ME, Starlinger M, Eichner M, Raybould HE, Becker HD, and Jehle EC. C-fos protein expression in the nucleus of the solitary tract correlates with cholecystokinin dose injected and food intake in rats. Brain Res 846: 1–11, 1999.[CrossRef][ISI][Medline]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
288/3/R751    most recent
00094.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via ISI Web of Science (17)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kobelt, P.
Right arrow Articles by Mönnikes, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kobelt, P.
Right arrow Articles by Mönnikes, H.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.